Can a gut pill stop kidney disease from becoming chronic?

NCT ID NCT07182422

Recruiting now Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether Kremezin (AST-120), a pill that absorbs toxins in the gut, can help kidneys recover after acute injury. Researchers will give 100 adults with acute kidney disease either Kremezin plus standard care or standard care alone for 14 days. They will measure toxin levels and kidney function over 6 months to see if the drug prevents progression to chronic kidney disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AST-120 (Kremezin), an oral medication that absorbs toxins in the gut
What this could lead to: If it works, this could help prevent acute kidney disease from turning into long-term chronic kidney disease and reduce heart-related complications.
What could go wrong: This is a small, early-phase trial with only 100 participants, so results may not apply to everyone. The treatment is short-term (14 days) and may not have lasting benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY DISEASE ACUTE KIDNEY INJURY (AKI)

Contacts and locations

Locations

Chang Gung Memorial Hospital, Taoyuan, Taiwan
RECRUITING

Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.